Redmile Group, LLC Immuno Gen, Inc. Transaction History

Redmile Group, LLC

$2.54 Billion
Q1 2024

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$12.46 - $29.95 $16.3 Million - $39.1 Million	-1,306,495 Reduced 7.37%	16,423,922 $487 Million
Q2 2023 Aug 14, 2023	BUY	$3.75 - $20.05 $36.3 Million - $194 Million	9,684,200 Added 120.36%	17,730,417 $335 Million
Q1 2023 May 15, 2023	SELL	$3.67 - $4.92 $1.79 Million - $2.39 Million	-486,600 Reduced 5.7%	8,046,217 $30.9 Million
Q4 2022 Feb 14, 2023	SELL	$4.55 - $6.31 $69,742 - $96,719	-15,328 Reduced 0.18%	8,532,817 $42.3 Million
Q3 2022 Nov 14, 2022	SELL	$4.48 - $6.47 $2.66 Million - $3.84 Million	-592,900 Reduced 6.49%	8,548,145 $40.9 Million

Q2 2022 Aug 15, 2022	SELL	$3.15 - $5.76 $242,235 - $442,944	-76,900 Reduced 0.83%	9,141,045 $41.1 Million
Q1 2022 May 16, 2022	BUY	$4.26 - $7.48 $4.09 Million - $7.18 Million	959,600 Added 11.62%	9,217,945 $43.9 Million
Q3 2021 Nov 15, 2021	SELL	$5.02 - $6.59 $3.13 Million - $4.1 Million	-622,600 Reduced 7.01%	8,258,345 $46.8 Million
Q2 2021 Aug 16, 2021	SELL	$5.79 - $8.6 $4.67 Million - $6.94 Million	-807,121 Reduced 8.33%	8,880,945 $58.5 Million
Q1 2021 May 17, 2021	SELL	$6.5 - $10.53 $5.46 Million - $8.85 Million	-840,113 Reduced 7.98%	9,688,066 $78.5 Million
Q4 2020 Feb 16, 2021	BUY	$3.7 - $7.66 $186,110 - $385,298	50,300 Added 0.48%	10,528,179 $67.9 Million
Q3 2020 Nov 16, 2020	SELL	$3.45 - $4.89 $5.28 Million - $7.48 Million	-1,529,100 Reduced 12.74%	10,477,879 $37.7 Million
Q2 2020 Aug 14, 2020	SELL	$3.32 - $5.34 $15.7 Million - $25.2 Million	-4,726,900 Reduced 28.25%	12,006,979 $55.2 Million
Q1 2020 May 15, 2020	BUY	$2.12 - $6.8 $4.44 Million - $14.2 Million	2,093,919 Added 14.3%	16,733,879 $57.1 Million
Q4 2019 Feb 14, 2020	BUY	$2.25 - $5.8 $52,650 - $135,720	23,400 Added 0.16%	14,639,960 $74.7 Million
Q3 2019 Nov 14, 2019	BUY	$2.22 - $3.39 $1.47 Million - $2.24 Million	661,766 Added 4.74%	14,616,560 $35.4 Million
Q2 2019 Aug 14, 2019	BUY	$1.8 - $3.3 $1.6 Million - $2.94 Million	891,027 Added 6.82%	13,954,794 $30.3 Million
Q1 2019 May 15, 2019	BUY	$2.41 - $5.91 $5.25 Million - $12.9 Million	2,179,160 Added 20.02%	13,063,767 $35.4 Million
Q4 2018 Feb 14, 2019	SELL	$3.94 - $9.7 $5.61 Million - $13.8 Million	-1,424,428 Reduced 11.57%	10,884,607 $52.2 Million
Q3 2018 Nov 14, 2018	SELL	$8.6 - $11.26 $59,400 - $77,772	-6,907 Reduced 0.06%	12,309,035 $117 Million
Q2 2018 Aug 14, 2018	BUY	$9.52 - $12.15 $24.9 Million - $31.8 Million	2,613,460 Added 26.94%	12,315,942 $120 Million
Q1 2018 May 15, 2018	SELL	$6.7 - $12.95 $8.07 Million - $15.6 Million	-1,204,480 Reduced 11.04%	9,702,482 $0
Q4 2017 Feb 14, 2018	BUY	$5.07 - $7.92 $14.4 Million - $22.5 Million	2,845,465 Added 35.3%	10,906,962 $69.9 Million
Q3 2017 Nov 14, 2017	BUY	$5.4 - $8.47 $43.5 Million - $68.3 Million	8,061,497	8,061,497 $61.7 Million

Others Institutions Holding IMGN

# of Institutions

Shares Held

1.41M

Call Options Held

Put Options Held

View Full List

About ImmunoGen, Inc.

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

More about IMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.

Account